tradingkey.logo
tradingkey.logo
Search

Kyverna Therapeutics Inc

KYTX
Add to Watchlist
7.310USD
+0.020+0.27%
Close 07-23 16:00ETQuotes delayed by 15 min
442.49MMarket Cap
LossP/E TTM

KYTX Income Statement

You can find the annual or quarterly income statement of Kyverna Therapeutics Inc here for insights into the performance and operational efficiency of Kyverna Therapeutics Inc.
Quarterly
Quarterly+Annual
Quarterly
Annual
YOY
Hide blank rows
FY2026Q1
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q4
FY2023Q1
FY2022Q4
Total revenue
----
----
----
----
----
----
----
----
----
-100.00%0.00
----
--282.00K
Revenue
----
----
----
----
----
----
----
----
----
-100.00%0.00
----
--282.00K
Operating expenses
-11.62%41.37M
-4.29%39.28M
-0.11%38.73M
32.82%44.41M
59.44%46.81M
91.99%41.04M
--38.77M
--33.44M
156.51%29.36M
136.03%21.38M
--11.45M
--9.06M
R&D expenses
-19.66%30.07M
-10.36%30.01M
4.33%30.46M
31.09%35.82M
66.55%37.43M
95.09%33.48M
--29.19M
--27.32M
158.02%22.48M
142.86%17.16M
--8.71M
--7.07M
Depreciation, depletion, and amortization
-29.94%351.00K
-28.60%402.00K
-18.64%454.00K
0.00%537.00K
-6.70%501.00K
6.03%563.00K
--558.00K
--537.00K
36.29%537.00K
41.98%531.00K
--394.00K
--374.00K
Other operating expenses
100.00%0.00
--0.00
--0.00
--0.00
---600.00K
----
----
----
----
----
----
----
Operating profit
11.62%-41.37M
4.29%-39.28M
0.11%-38.73M
-32.82%-44.41M
-59.44%-46.81M
-91.99%-41.04M
---38.77M
---33.44M
-156.51%-29.36M
-143.61%-21.38M
---11.45M
---8.78M
Net non-operating interest income (expenses)
Non-operating interest income
-17.63%2.33M
-46.71%1.91M
-54.09%2.00M
-49.64%2.36M
3.29%2.83M
353.11%3.58M
--4.36M
--4.69M
683.67%2.73M
165.66%789.00K
--349.00K
--297.00K
Non-operating interest expense
2568.00%667.00K
1544.44%444.00K
-78.79%7.00K
-64.10%14.00K
-43.18%25.00K
-42.55%27.00K
--33.00K
--39.00K
0.00%44.00K
14.63%47.00K
--44.00K
--41.00K
Special income (expenses)
100.00%0.00
--0.00
--0.00
--0.00
---600.00K
----
----
----
----
----
----
----
Other non-operating income (expenses)
22.22%-21.00K
325.00%17.00K
-17.78%-53.00K
8.70%-21.00K
-3.85%-27.00K
112.50%4.00K
---45.00K
---23.00K
-766.67%-26.00K
-239.13%-32.00K
---3.00K
--23.00K
Income before tax
10.99%-39.73M
-0.84%-37.80M
-6.65%-36.79M
-46.10%-42.08M
-67.22%-44.63M
-81.40%-37.49M
---34.49M
---28.80M
-139.55%-26.69M
-143.26%-20.67M
---11.14M
---8.50M
Income tax
----
--0.00
----
----
----
----
----
----
----
----
----
----
Income after tax
10.99%-39.73M
-0.84%-37.80M
-6.65%-36.79M
-46.10%-42.08M
-67.22%-44.63M
-81.40%-37.49M
---34.49M
---28.80M
-139.55%-26.69M
-143.26%-20.67M
---11.14M
---8.50M
Net income from continuous operations
10.99%-39.73M
-0.84%-37.80M
-6.65%-36.79M
-46.10%-42.08M
-67.22%-44.63M
-81.40%-37.49M
---34.49M
---28.80M
-139.55%-26.69M
-143.26%-20.67M
---11.14M
---8.50M
Net income attributable to controlling interests
10.99%-39.73M
-0.84%-37.80M
-6.65%-36.79M
-46.10%-42.08M
-67.22%-44.63M
-81.40%-37.49M
---34.49M
---28.80M
-139.55%-26.69M
-143.26%-20.67M
---11.14M
---8.50M
Net income attributable to common shareholders
10.99%-39.73M
-0.84%-37.80M
-6.65%-36.79M
-46.10%-42.08M
-67.22%-44.63M
-81.40%-37.49M
---34.49M
---28.80M
-139.55%-26.69M
-143.26%-20.67M
---11.14M
---8.50M
Basic earnings per share
36.35%-0.66
7.61%-0.80
-6.02%-0.85
-45.76%-0.97
-66.83%-1.03
-109.77%-0.87
---0.80
---0.67
-126.81%-0.62
-98.63%-0.41
---0.27
---0.21
Diluted earnings per share
36.35%-0.66
7.61%-0.80
-6.02%-0.85
-45.76%-0.97
-66.83%-1.03
-109.77%-0.87
---0.80
---0.67
-126.81%-0.62
-98.63%-0.41
---0.27
---0.21
Dividend per share
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
Currency unit
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
Audit opinions
----
----
----
----
----
----
----
----
----
----
----
----

FAQs

How do I read Kyverna Therapeutics Inc's income statement on TradingKey?

Start with total revenue, then review cost of revenue, gross profit, operating expenses, operating profit, income before tax, net income, and EPS. Revenue shows the scale of the business, while margins and profit lines show whether that revenue is being converted into earnings efficiently.

What is the difference between quarterly and annual income statements?

A quarterly income statement shows performance for a three-month fiscal period, while an annual income statement summarizes the full fiscal year. Quarterly data is useful for tracking recent momentum and seasonality, while annual data is better for judging long-term growth, profitability, and business cycles.

What does YOY mean on the income statement page?

YOY means year over year. It compares a financial metric with the same period in the previous year, such as this quarter's revenue versus revenue in the same quarter last year. YOY comparison helps investors see growth trends while reducing the impact of normal seasonal changes.

Which income statement metrics matter most when analyzing KYTX stock?

Important metrics include revenue growth, gross profit, gross margin, operating profit, operating margin, net income, EPS, R&D expenses, SG&A expenses, and tax expense. Investors usually look at these together to judge whether the company is growing, controlling costs, and improving profitability.

What was Kyverna Therapeutics Inc's net income for the year?

Kyverna Therapeutics Inc posted -161.31M in net income for fiscal year 2025.

How much net income did Kyverna Therapeutics Inc post in the last quarter?

Kyverna Therapeutics Inc reported -39.73M in net income for the latest quarter。

What was Kyverna Therapeutics Inc's annual operating profit?

Kyverna Therapeutics Inc's operating income was -169.23M for fiscal year 2025.

How is EPS related to the income statement?

EPS, or earnings per share, is based on net income divided by the number of shares outstanding. It helps investors understand how much profit the company generated for each share, but it should be reviewed alongside share count changes, margins, cash flow, and valuation metrics.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.